Clinical Evidence
DanGer Shock Randomized Controlled Trial (RCT) Confirms Routine Use of Impella CP® Heart Pump Improves Survival in Heart Attack with Shock
This investigator-initiated study is the first RCT of Impella in cardiogenic shock (CS), assessed the efficacy of Impella CP® with or without SmartAssist® heart pumps in treating patients with AMICS shock due to STEMI, undergoing emergency PCI.4
DanGer Shock Results from Dr. Jacob Møller at ACC 2024
Jacob Møller, MD, the principal investigator of the DanGer Shock trial, discusses study results he presented at ACC 2024.
Key Findings from the National Cardiogenic Shock Initiative Study
Early Utilization of Mechanical Circulatory Support in Acute Myocardial Infarction Complicated by Cardiogenic Shock1,2,3
- Identify and support cardiogenic shock early
- Turn down titriation of inotropes aggressively
- Identify inadequate left ventricular (LV) support and escalate, if CPO <0.6
- Identify right ventricular (RV) dysfunction early and support
- Systematically use right heart catheter (RHC) to guide therapy
Clinical Evidence has Established Safety and Effectiveness and Validated Best Practices
Clinical evidence of Impella systems has established safety and effectiveness and validated best practices.
Recently Published Clinical Trials
European Best Practices: From Patient Selection to Escalation Strategies – Mechanical Circulatory Support in Cardiogenic Shock
Experts throughout Europe have contributed to these publications in the European Heart Journal Supplements. Their articles discuss best practices for successfully managing mechanical circulatory support (MCS) in patients with cardiogenic shock.
References
- Tehrani, B.N., et al. (2019). JACC. 73, 1659-1669.
- Basir, M.B., et al. (2019). Catheter Cardiovasc Interv, 93(7), 1173-1183.
- O’Neill, W.W., TCT 2020.
- Møller, J., et al. (2024). Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med.
Discover More About Cardiogenic Shock
NPS-2632